Zoster Vaccine Phase 4 Glioblastoma Study Registered, Apr 23
ClinicalTrials.gov Studies
Summary
Phase 4 clinical trial NCT07546669 was registered on ClinicalTrials.gov investigating whether adding herpes zoster (shingles) vaccination to standard trimodality care (surgery, radiation, chemotherapy) improves local control, overall survival, and progression-free survival in patients with histologically confirmed glioblastoma. The study includes approximately two arms: a vaccination group receiving standard care plus zoster vaccine, and a control group receiving standard care without additional vaccination. An optional experimental arm based on patient preference will examine immunological effectiveness of adoptive transfer of autologous CMV-specific T cells.
“We hypothesize that the additional vaccination against herpes zoster, after surgical resection followed by irradiation therapy and chemotherapy of patients with glioblastoma will lead to a superior local control, overall and progression free survival.”
About this source
ClinicalTrials.gov is the NIH-run registry of every clinical trial conducted in the United States, plus most international trials sponsored by US-based companies or institutions. By federal law, sponsors must register Phase 2 through Phase 4 studies before enrolling patients and post results within a year of completion. This feed tracks every new trial registration and study update, around 700 a month: drug interventions, device studies, behavioral protocols, observational research. Watch this if you scout drug candidates moving into mid or late-stage development, monitor competitor pipelines, or follow rare disease research where new trials signal patient hope. GovPing parses sponsor, phase, intervention, and target indication on each entry.
What changed
A new Phase 4 clinical trial has been registered on ClinicalTrials.gov, evaluating the efficacy of zoster vaccination as an adjunct to standard-of-care treatment for glioblastoma. Glioblastoma patients who have undergone surgical resection followed by irradiation therapy and chemotherapy will be enrolled and randomized to receive either additional zoster vaccination or standard care alone. The study hypothesis is that the vaccine will improve local tumour control and overall and progression-free survival. An exploratory arm based on patient preference will evaluate the immunological effectiveness of autologous CMV-specific T cell transfer.
For oncology clinical teams, trial sponsors, and institutional review boards, this registration signals an active Phase 4 study that may accept eligible glioblastoma patients and represents a specific post-authorization investigation of an approved vaccine in an oncology context. Sites with relevant expertise should review eligibility criteria and consider whether the trial aligns with their patient population and research programmes.
Archived snapshot
Apr 24, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
Efficacy of Zoster Vaccination in Glioblastoma Patients
Phase 4 NCT07546669 Kind: PHASE4 Apr 23, 2026
Abstract
In modern practice a trimodality treatment has emerged as standard of care for histologically confirmed glioblastoma.
We hypothesize that the additional vaccination against herpes zoster, after surgical resection followed by irradiation therapy and chemotherapy of patients with glioblastoma will lead to a superior local control, overall and progression free survival. In an additional experimental setting based on patient preference the immunological effectiveness of the adoptive transfer of autologous polyclonal cytomegalovirus (CMV) specific T cells will be examined.
Conditions: Glioblastoma (GBM)
Interventions: Additional vaccination against shingles (herpes zoster), Standard of care treatment without additional vaccination
Related changes
Get daily alerts for ClinicalTrials.gov Studies
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from NIH.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when ClinicalTrials.gov Studies publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.